ALGS Graph | Aligos Therapeutics, Inc.

ALGS Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

2026-06-30: Revenue $0.00; Research and development $24.05M; Operating expenses $29.67M; Income tax $2.81M.
2026-03-31: Revenue $2.83M; Research and development $23.35M; Operating expenses $29.76M; Income tax $317.00K.
2025-12-31: Revenue $169.00K*; Research and development $17.04M*; Operating expenses $21.98M*; Income tax $30.00K*.
2025-09-30: Revenue $741.00K; Research and development $23.94M; Operating expenses $29.10M; Income tax $56.00K.

Revenue flow

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2026-06-30	$0.00	$24.05M	$29.67M	$2.81M	-$1.50M
2026-03-31	$2.83M	$23.35M	$29.76M	$317.00K	-$23.04M
2025-12-31	$169.00K*	$17.04M*	$21.98M*	$30.00K*	-$19.88M*
2025-09-30	$741.00K	$23.94M	$29.10M	$56.00K	-$31.54M
2025-06-30	$965.00K	$13.98M	$19.53M	$185.00K	-$15.86M
2025-03-31	$311.00K	$14.50M	$19.55M	$43.00K	$43.09M
2024-09-30	$1.25M	$16.77M	$21.40M	$91.00K	-$19.26M
2024-06-30	$1.06M	$21.10M	$27.48M	$189.00K	$5.06M
2024-03-31	$694.00K	$16.37M	$23.03M	$24.00K	-$34.86M
2023-09-30	$1.08M	$15.87M	$22.31M	$29.00K	-$18.04M
2023-06-30	$4.29M	$16.78M	$26.03M	$757.00K	-$18.79M
2023-03-31	$140.00K	$18.14M	$26.64M	$39.00K	-$22.95M
2022-09-30	$0.00	$17.79M	$23.05M	-$43.00K	-$18.62M
2022-06-30	$0.00	$16.51M	$24.09M	$47.00K	-$19.92M
2022-03-31	(m)	$31.68M	$38.13M	$53.00K	-$35.62M
2021-09-30	(m)	$28.13M	$34.60M	$126.00K	-$33.12M
2021-06-30	(m)	$24.55M	$31.11M	$28.00K	-$29.82M
2021-03-31	(m)	$22.87M	$28.65M	$45.00K	-$27.67M
2020-09-30	(m)	$17.33M	$21.56M	$0.00	-$33.30M
2020-06-30	(m)	$17.18M	$21.27M	-$59.00K	-$20.80M
2020-03-31	(m)	$17.30M	$20.72M	(m)	-$20.03M
2019-09-30	(m)	$11.73M	$14.50M	(m)	-$14.05M

Revenue and expense 6 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2026-06-30	$2.83M	$47.40M	$59.43M	$3.13M	-$24.54M
2025-06-30	$1.28M	$28.48M	$39.09M	$228.00K	$27.23M
2024-06-30	$1.75M	$37.46M	$50.51M	$213.00K	-$29.80M
2023-06-30	$4.43M	$34.92M	$52.67M	$796.00K	-$41.75M
2022-06-30	$0.00	$48.19M	$62.21M	$99.00K	-$55.54M
2021-06-30	(m)	$47.42M	$59.76M	$74.00K	-$57.49M
2020-06-30	(m)	$34.48M	$41.99M	-$58.00K	-$40.83M

Revenue and expense 9 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2025-09-30	$2.02M	$52.41M	$68.19M	$284.00K	-$4.31M
2024-09-30	$3.00M	$54.24M	$71.91M	$304.00K	-$49.06M
2023-09-30	$5.52M	$50.78M	$74.98M	$825.00K	-$59.79M
2022-09-30	$0.00	$65.98M	$85.27M	$57.00K	-$74.16M
2021-09-30	(m)	$75.56M	$94.36M	$201.00K	-$90.62M
2020-09-30	(m)	$51.81M	$63.55M	-$58.00K	-$74.12M
2019-09-30	(m)	$29.07M	$35.61M	(m)	-$34.08M

Revenue and expense 12 month

Period end	Revenue	Research and development	Operating expenses	Income tax	Net income
2025-12-31	$2.19M	$69.45M	$90.17M	$314.00K	-$24.19M
2024-12-31	$3.61M	$70.27M	$93.10M	$331.00K	-$131.21M
2023-12-31	$6.19M	$73.04M	$103.66M	$795.00K	-$87.68M
2022-12-31	$0.00	$85.08M	$111.49M	$106.00K	-$96.05M
2021-12-31	$0.00	$104.15M	$132.68M	$143.00K	-$128.33M
2020-12-31	$0.00	$79.89M	$97.83M	$161.00K	-$108.54M
2019-12-31	(m)	$44.04M	$54.04M	$85.00K	-$52.26M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Lineage Cell Therapeutics, Inc. (LCTX)	United States	$0.241B	-10.35
Protalix BioTherapeutics, Inc. (PLX)		$0.221B	9.87
ANAVEX LIFE SCIENCES CORP. (AVXL)	United States	$0.218B	-18.37
SUTRO BIOPHARMA, INC. (STRO)	United States	$0.260B	-3.05
Alector, Inc. (ALEC)	United States	$0.213B	-1.90
Invivyd, Inc. (IVVD)	United States	$0.270B	-2.42
Compass Therapeutics, Inc. (CMPX)	United States	$0.204B	-5.35
PALISADE BIO, INC. (PALI)	United States	$0.275B	-11.41
Lexeo Therapeutics, Inc. (LXEO)	United States	$0.278B	-4.19
Protara Therapeutics, Inc. (TARA)	United States	$0.198B	-3.22